Company Overview
Company Type: Public Company
Website: www.tryptherapeutics.com
Number of Employees: -
Ticker: TRYP (CNSX)
Year Founded: 2019


Business Description
Tryp Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing psilocybin-related molecules. The company’s Psilocybin-For-Neuropsychiatric Disorders (PFN) program focuses on the development of synthetic psilocybin-related molecules as a new class of drug for the treatment of binge eating, chronic pain, and other indications. Its program candidate includes TRP-8803, a psilocybin-based drug product for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. Tryp Therapeutics Inc. was incorporated in 2019 and is based in Kelowna, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
6.3
Total Enterprise Value
6.3
EBIT
(5.8)
Cash & ST Invst.
1.3
P/Diluted EPS Before Extra
NM
Net Income
(5.7)
Total Debt
1.2
Price/Tang BV
NM
Total Assets
1.6
Currency in CAD in mm, LTM as of May-31-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023

Key Professionals
Name
Title
Carroll, Jason 
Chief Executive Officer
Gilligan, James P.
President & Chief Scientific Officer
Garner, William James
Founder & MD
Kuo, James S.
Co-Founder & Director
O'Neill, Jim 
Chief Financial Officer
Taubenfeld, Sidney 
Chief Operating Officer
Willis, Joy 
Director of Investor Relations
Molloy, Peter 
Chief Business Officer
Silverman, Michael H.
Chief Medical Officer

Key Board Members
Name
Title
Jull, P. Gage
Independent Chairman of the Board
Kuo, James S.
Co-Founder & Director
Carhart-Harris, Robin L.
Chairman of Scientific Advisory Board
Castellanos, Joel 
Member of Scientific Advisory Board
Clauw, Daniel J.
Member of Scientific Advisory Board
Ntoumenopoulos, Christopher 
Independent Director
Ott, Derek 
Member of Scientific Advisory Board
Schmidt, William K.
Member of Scientific Advisory Board
Wevrick, Rachel 
Member of Scientific Advisory Board


Primary Industry Classification
Pharmaceuticals


Primary Office Location
301 - 1665 Ellis Street | Kelowna, BC | V1Y 2B3 | Canada

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.06
Market Cap (mm)
5.4
Open
 0.06
Shares Out. (mm)
90.3
Previous Close
 0.06
Float %
50.1%
Change on Day
(0.01)
Shares Sold Short (mm)
-
Change % on Day
(14.3)%
Dividend Yield %
-
Day High/Low
 0.06/ 0.06
Diluted EPS Excl. Extra Items
(0.06)
52 wk High/Low
 0.18/ 0.05
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0034
Avg 3M Dly Vlm (mm)
0.02
Beta 5Y
(0.81)


 
Delayed Quote** | Last Updated on Oct-05-2023 12:00 AM (GMT-5)
CNSX:TRYP - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Oct-04-2023
-
Private Placement
Target
Tryp Therapeutics Inc. (CNSX:TRYP)


0.11
Apr-12-2023
Apr-27-2023
Private Placement
Target
Tryp Therapeutics Inc. (CNSX:TRYP)


1.59
Feb-04-2022
-
Private Placement
Target
Tryp Therapeutics Inc. (CNSX:TRYP)


4.70
Feb-05-2021
Feb-16-2021
Private Placement
Target
Tryp Therapeutics Inc. (CNSX:TRYP)


1.58
Nov-12-2020
Dec-17-2020
Public Offering
Target
Tryp Therapeutics Inc. (CNSX:TRYP)


3.42
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-04-2023
Private Placements
Tryp Therapeutics Inc. announced that it expects to receive AUD 0.175 million in funding
Aug-03-2023
Executive Changes - CEO
Tryp Therapeutics Announces Appointment of Jason Carroll as New Chief Executive Officer, Effective October 1, 2023
Aug-02-2023
Executive/Board Changes - Other
Tryp Therapeutics Inc. Announces the Passing of David Tousley, Director
Aug-01-2023
Product-Related Announcements
Tryp Therapeutics Receives Confirmation from FDA to Proceed with Phase 2A Clinical Trial in Patients with IBS At Massachusetts General Hospital
Jun-20-2023
End of Lock-Up Period
3,043,860 Common Shares of Tryp Therapeutics Inc. are subject to a Lock-Up Agreement Ending on 20-JUN-2023.


Advisors
Most Recent Auditor
Smythe LLP
Private Placement Advisors
Alto Capital Pty Ltd, Westar Capital Limited
Public Offering Advisors
Pushor Mitchell LLP, Smythe LLP


Most Recent Auditor
Smythe Ratcliffe


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Ladenburg Thalmann & Company
Higgins, Michael John
Jan 05, 2023 09:18 AM
TRYP
TRP-8802’s Phase 2a Binge Eating Interim Data: ~80% Episode Reduction; Reit Buy
Reports
16
CFRA Equity Research

Jan 03, 2023 10:33 AM
TRYP
Tryp Therapeutics Inc.
Reports
9
Ladenburg Thalmann & Company
Higgins, Michael John
Dec 15, 2022 04:33 AM
TRYP
F4Q’22 Reported; Phase 2a Binge Eating Interim Data 1Q’23; Reiterate Buy
EPS Estimates*
15
Ladenburg Thalmann & Company
Higgins, Michael John
Oct 05, 2022 04:33 AM
TRYP
Tryp Unveils TRP-8803 (IV Psilocin): Targeting 2 Hour Therapy Sessions; Reit Buy
EPS Estimates*
15
Smart Insider Ltd.

Feb 23, 2022 03:18 AM
TRYP
Tryp Therapeutics Inc: 1 director
Reporting Results*
1
Ladenburg Thalmann & Company
Higgins, Michael John
Dec 23, 2021 06:09 AM
TRYP
F4Q’21 Reported; Psilocybin Phase 2a’s Start 1H’22; Reit Buy, PT $2.00 to $1.50
EPS Estimates*
15
Ladenburg Thalmann & Company
Higgins, Michael John
Nov 19, 2021 05:12 AM
TRYP
With FDA Feedback, Psilocybin Eating Disorder Phase 2a to Start 1Q’22; Buy
Reports
13
Ladenburg Thalmann & Company
Higgins, Michael John
Oct 21, 2021 05:06 AM
TRYP
“Clinical Hold” on Proposed Phase 2a in Eating Disorders; Reiterate Buy, $2.00 PT
Reports
13
Ladenburg Thalmann & Company
Higgins, Michael John
Aug 26, 2021 04:33 AM
TRYP
Tryp to Reset the Treatment of Brain Disorders; Initiate at Buy, $2.00 PT
Initiation of Coverage*
46


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Garner M.D., M.P.H., MPH, William James

38,420,000

42.53

2.9

Apr-26-2023


Kuo M.B.A., M.D., James S.

6,000,000

6.64

0.5

May-22-2022


Jull B.Sc., C.F.A., M.B.A., P. Gage

463,829

0.51

0.0

Oct-19-2022


Molloy ASIP, B.A., C.F.A., Peter 

200,000

0.22

0.0

May-22-2022


1st Capital Management Group GmbH

0

0.00

0.0

Jun-30-2023



 



Top Buyers
No Top Buyers data available.

Top Sellers
Sellers
Common Stock Equivalent Held
Change
1st Capital Management Group GmbH
0
(40,000)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Psilocybin, TRP-1001 (Future), TRP-8802 (Future), TRP-8803 (Future)


Upcoming Events
Date/Time
Type
Nov-13-2023
Estimated Earnings Release Date (S&P Global Derived)
Dec-18-2023
End of Lock-Up Period
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Oct-04-2023
-
Tryp Therapeutics Inc. (CNSX:TRYP)
SEDAR
News Releases
268 KB
Aug-04-2023
-
Tryp Therapeutics Inc. (CNSX:TRYP)
SEDAR
News Releases
76 KB
Aug-01-2023
-
Tryp Therapeutics Inc. (CNSX:TRYP)
SEDAR
News Releases
72 KB
Jul-31-2023
-
Tryp Therapeutics Inc. (CNSX:TRYP)
SEDAR
Interim Financial Statements
299 KB
May-24-2023
-
Tryp Therapeutics Inc. (CNSX:TRYP)
SEDAR
News Releases
110 KB
May-01-2023
-
Tryp Therapeutics Inc. (CNSX:TRYP)
SEDAR
Material Change Report
181 KB
Apr-28-2023
Feb-28-2023
Tryp Therapeutics Inc. (CNSX:TRYP)
SEDAR
Interim Financial Statements
351 KB
Apr-27-2023
-
Tryp Therapeutics Inc. (CNSX:TRYP)
SEDAR
Securities Acquisition Filings (Early Warning)
158 KB
Apr-27-2023
-
Tryp Therapeutics Inc. (CNSX:TRYP)
SEDAR
News Releases
296 KB
Apr-12-2023
-
Tryp Therapeutics Inc. (CNSX:TRYP)
SEDAR
News Releases
253 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Jull B.Sc., C.F.A., M.B.A., P. Gage (Independent Chairman of the Board)
Oct-11-2022 - Oct-19-2022
Common Shares
71,429
11,352
Open Market Acquisition
18.20
Multiple
-
Oct-11-2022
Common Shares
32,500
5,143
Open Market Acquisition
-
Exchange Announcement
-
Oct-19-2022
Common Shares
38,738
6,176
Open Market Acquisition
-
Exchange Announcement
-
Oct-19-2022
Common Shares
191
33
Open Market Acquisition
-
Exchange Announcement
Garner M.D., M.P.H., MPH, William James (Founder & MD)
Apr-22-2022
Common Shares
20,000,000
3,244,825
Private Acquisition
108.58
Multiple
Garner M.D., M.P.H., MPH, William James (Founder & MD)
Feb-22-2022
Common Shares
5,000,000
1,078,620
Open Market Acquisition
37.26
Multiple
Garner M.D., M.P.H., MPH, William James (Founder & MD)
Oct-25-2021 - Oct-26-2021
Common Shares
25,000
8,063
Open Market Acquisition
0.19
Multiple
-
Oct-25-2021
Common Shares
5,000
1,704
Open Market Acquisition
-
Exchange Announcement
-
Oct-26-2021
Common Shares
20,000
6,359
Open Market Acquisition
-
Exchange Announcement
Garner M.D., M.P.H., MPH, William James (Founder & MD)
Aug-24-2021 - Aug-25-2021
Common Shares
184,500
71,168
Open Market Acquisition
1.40
Multiple
-
Aug-24-2021
Common Shares
30,000
11,411
Open Market Acquisition
-
Exchange Announcement
-
Aug-25-2021
Common Shares
4,000
1,696
Open Market Acquisition
-
Exchange Announcement
-
Aug-25-2021
Common Shares
2,500
1,011
Open Market Acquisition
-
Exchange Announcement
-
Aug-24-2021
Common Shares
34,500
12,683
Open Market Acquisition
-
Exchange Announcement
-
Aug-24-2021
Common Shares
25,500
9,925
Open Market Acquisition
-
Exchange Announcement
-
Aug-25-2021
Common Shares
2,500
1,007
Open Market Acquisition
-
Exchange Announcement
-
Aug-25-2021
Common Shares
17,500
6,929
Open Market Acquisition
-
Exchange Announcement
-
Aug-24-2021
Common Shares
10,000
3,823
Open Market Acquisition
-
Exchange Announcement
-
Aug-24-2021
Common Shares
4,500
1,713
Open Market Acquisition
-
Exchange Announcement
-
Aug-25-2021
Common Shares
2,500
979
Open Market Acquisition
-
Exchange Announcement
-
Aug-25-2021
Common Shares
1,000
387
Open Market Acquisition
-
Exchange Announcement
-
Aug-24-2021
Common Shares
1,000
384
Open Market Acquisition
-
Exchange Announcement
-
Aug-24-2021
Common Shares
14,500
5,504
Open Market Acquisition
-
Exchange Announcement
-
Aug-25-2021
Common Shares
1,500
587
Open Market Acquisition
-
Exchange Announcement
-
Aug-25-2021
Common Shares
28,500
11,436
Open Market Acquisition
-
Exchange Announcement
-
Aug-24-2021
Common Shares
4,500
1,692
Open Market Acquisition
-
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Jull, P. Gage
Independent Chairman of the Board
(416) 860-7614
-

Kuo, James S.
Co-Founder & Director
(183) 381-1879x7
-

Carhart-Harris, Robin L.
Chairman of Scientific Advisory Board
-
-

Castellanos, Joel 
Member of Scientific Advisory Board
-
-

Clauw, Daniel J.
Member of Scientific Advisory Board
-
-

Ntoumenopoulos, Christopher 
Independent Director
-
-

Ott, Derek 
Member of Scientific Advisory Board
-
-

Schmidt, William K.
Member of Scientific Advisory Board
-
-

Wevrick, Rachel 
Member of Scientific Advisory Board
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Carroll, Jason 
Chief Executive Officer
-
-

Gilligan, James P.
President & Chief Scientific Officer
-
-
JimGilligan@Herborium.com
Garner, William James
Founder & MD
-
-

Kuo, James S.
Co-Founder & Director
(183) 381-1879x7
-

O'Neill, Jim 
Chief Financial Officer
-
-

Taubenfeld, Sidney 
Chief Operating Officer
-
-

Willis, Joy 
Director of Investor Relations
-
-

Molloy, Peter 
Chief Business Officer
-
-

Silverman, Michael H.
Chief Medical Officer
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
